Ex-Chief Of Europe's Regulatory Agency To Be Kept On A Tight Rein
This article was originally published in The Pink Sheet Daily
Former executive director of the European Medicines Agency, Thomas Lönngren, told to limit his pharmaceutical industry roles; FDA Commissioners have it easier.
You may also be interested in...
European Notebook: EMA Conflict Of Interest Rules; EU Unitary Patent; EMA Adverse Event Literature Screening
EMA tightens rules on the revolving door between industry and scientific (if not regulators); the European unitary patent proposal survives Spain's judicial challenge; Switzerland amends its drug pricing procedures, and more in this month's column.
Industry and regulators are showing more interest in implementing adaptive licensing in Europe. Both sides agree that increased trust and transparency could be stepping stones towards this goal.
European Commission intervention has stopped duplicate generic applications. EMA hopes to end its budget row with the EU Parliament by focusing on transparency and conflict of interest disclosures.